Home /
Immunotherapy – St. Bartholomew’s Hospital – Treatment Details
|
|
| Description: |
| Patients: This Phase II study involved 29 patients with malignant pleural mesothelioma. None of these patients had been administered previous chemotherapy or immunotherapy.
Treatment: The treatment consisted of the administration of human recombinant Interleukin-2. Toxicity: Toxicities included fever (grade 2), cutaneous toxicity, nausea and vomiting (grade 1), and chest pains. Results: Overall median survival was 9 months from the date of first treatment. Support: The cost of the interleukin-2 was subsidized by Chiron UK Limited. Chiron manufactures interleukin-2 (Proleukin). Correspondence: R.M. Rudd, MD |
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."